Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 1Neoplastic Cells, Circulating 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 20lenvatinib 18Hepatectomy 17Blood Specimen Collection 12Immune Checkpoint Inhibitors 11atezolizumab 9Liver Transplantation 9Surgical Procedures, Operative 7Radiofrequency Ablation 7Observation 7Bevacizumab 7regorafenib 5gadolinium ethoxybenzyl DTPA 5sintilimab 4donafenib 4camrelizumab 4Radiotherapy 4Magnetic Resonance Spectroscopy 4tislelizumab 3spartalizumab 3Polymerase Chain Reaction 3Neoadjuvant Therapy 3Mass Spectrometry 3Immunohistochemistry 3Doxorubicin 3Angiogenesis Inhibitors 3toripalimab 2pembrolizumab 2entecavir 2apatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Carcinoma, Hepatocellular × lanreotide × Clear all
NCT02973204 2021-04-28

Circulating Tumor Cells and Tumor DNA in HCC and NET

University of Aarhus

Completed
167 enrolled
EndocrineGastrointestinalNET

Carcinoma, Hepatocellular, Neoplastic Cells, Circulating, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡